All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @auralis.peptides.biotech on TikTok · 10s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @auralis.peptides.biotech's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Thank you for your support.
  2. 0:01I hope you enjoyed this video.
  3. 0:02I hope you enjoyed it.
  4. 0:03I hope you enjoyed it.
  5. 0:04I hope you enjoyed it.
  6. 0:06I hope you enjoyed it.
  7. 0:07I hope you enjoyed it.
  8. 0:08Have a good day.

CJC-1295 and ipamorelin claims from @auralis.peptides.biotech

Auralis Peptides | Biotech

TikTok creator

15.2K viewsWatch on TikTok

Quick answer

The transcript contains no medical claims, dosing information, or mechanism descriptions. The post promotes CJC-1295 without DAC combined with ipamorelin, a GHRH analog plus ghrelin mimetic stack intended to stimulate pulsatile growth hormone release, via hashtags and branding only. Clinical evaluation is therefore based on the implied efficacy claims for muscle and sleep made by the promotional framing rather than any spoken content.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For CJC-1295 and ipamorelin claims from @auralis.peptides.biotech, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

CJC-1295 and ipamorelin claims from @auralis.peptides.biotech is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this cjc-1295 video claims cluster

Best for searchers checking whether growth-hormone peptide claims fit evidence, access, and safety realities.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "CJC-1295 and ipamorelin claims from @auralis.peptides.biotech" from Auralis Peptides | Biotech. We read the clip as a Peptide social video fact-checks claim about CJC-1295, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The transcript contains no medical claims, dosing information, or mechanism descriptions.

The reason this review is not generic is the source wording and the canonical claim label "peptides cjc 1295 no dac ipamorelin de auralis peptides." In this clip, the useful excerpt is: "Thank you for your support." That wording changes the review because it points to CJC-1295 evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. CJC-1295 decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Ipamorelin's selectivity for GH release with minimal cortisol or prolactin impact was established by Raun et al.
People who land here are usually comparing the CJC-1295 claim with [object Object].
The strongest next step is to compare the claim with FormBlends' CJC-1295 guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The transcript contains no medical claims, dosing information, or mechanism descriptions.

FormBlends verdict

CJC-1295 evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The transcript contains no medical claims, dosing information, or mechanism descriptions. The post promotes CJC-1295 without DAC combined with ipamorelin, a GHRH analog plus ghrelin mimetic stack intended to stimulate pulsatile growth hormone release, via hashtags and branding only. Clinical evaluation is therefore based on the implied efficacy claims for muscle and sleep made by the promotional framing rather than any spoken content.
  • CJC-1295 no DAC has a half-life of roughly 30 minutes, making it pharmacokinetically distinct from the DAC version studied by Teichman et al. (2006, JCEM). Most cited research uses the longer-acting DAC formulation.
  • Ipamorelin's selectivity for GH release with minimal cortisol or prolactin impact was established by Raun et al. (1998, European Journal of Endocrinology) in animal models. Human data is limited.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • CJC-1295 no DAC has a half-life of roughly 30 minutes, making it pharmacokinetically distinct from the DAC version studied by Teichman et al. (2006, JCEM). Most cited research uses the longer-acting DAC formulation.
  • Ipamorelin's selectivity for GH release with minimal cortisol or prolactin impact was established by Raun et al. (1998, European Journal of Endocrinology) in animal models. Human data is limited.
  • The deep sleep angle has the most scientific support: GHRH analogs have been shown to increase slow-wave sleep in healthy men (Frieboes et al., 1995, Neuroendocrinology).
  • A 2007 meta-analysis in Annals of Internal Medicine found GH supplementation in healthy adults increased lean mass but did not improve strength, complicating the muscle-building narrative.
  • Neither CJC-1295 nor ipamorelin is FDA-approved. The FDA has taken enforcement action against compounding pharmacies producing these peptides, and their legal status for consumer sale is unsettled.
  • Long-term safety data for repeated GH secretagogue use in healthy, non-deficient adults does not exist in the peer-reviewed literature. No one knows the multi-year risk profile.
  • This post is promotional content. It contains no spoken medical claims because it contains almost no spoken content at all. Regulatory and clinical red flags come from the branding and implied use case, not a falsifiable statement.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @auralis.peptides.biotech actually say?

Honestly? Almost nothing. The transcript is entirely filler, a repetitive loop of "I hope you enjoyed this video" and "have a good day." There are no clinical claims, no dosing instructions, no mechanism explanations. The actual content of the video, if any, lives in the visuals or a voiceover that wasn't captured here. So this fact-check is working from the caption and hashtags: CJC-1295 no DAC, ipamorelin, growth hormone, muscles, and deep rest.

That means we're fact-checking the implicit promise of the post, that combining CJC-1295 without DAC and ipamorelin does something meaningful for muscle and sleep. That's a real claim worth examining, even if the creator didn't say it out loud.

Does the science back this up?

The pharmacology here is real, but the evidence base is thin for the specific outcomes being implied. CJC-1295 without DAC is a growth hormone releasing hormone (GHRH) analog with a short half-life, roughly 30 minutes. Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin. Used together, they work on different receptors to stimulate pulsatile GH release, which is the rationale for combining them.

What does the research actually show? A study by Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) demonstrated that CJC-1295 with DAC raised IGF-1 levels significantly in healthy adults, but the no-DAC version is pharmacokinetically different and less studied in published trials. Ipamorelin's selectivity was characterized by Raun et al. (1998, European Journal of Endocrinology), showing it stimulates GH with minimal effect on cortisol or prolactin, which is considered an advantage over older secretagogues. Combined GHRH plus secretagogue stacking has theoretical synergy, but peer-reviewed trials specifically on the no-DAC plus ipamorelin combination in healthy adults are sparse. Most evidence is either animal data or extrapolated from related compounds.

What did they get wrong (or right)?

They didn't make specific claims, so there's nothing to directly rebut. But the framing of the hashtags deserves scrutiny. "Deep rest" as a benefit of this stack is the most defensible angle: GH secretion is naturally highest during slow-wave sleep, and some research suggests secretagogues may amplify this. Frieboes et al. (1995, Neuroendocrinology) found GHRH administration increased slow-wave sleep in healthy men. That's plausible biological reasoning.

The muscle angle is murkier. Elevated GH and downstream IGF-1 do support protein synthesis, but the jump from "elevated GH pulse" to "more muscle" in healthy, non-deficient adults is not cleanly supported. A meta-analysis by Liu et al. (2007, Annals of Internal Medicine) found GH supplementation in healthy older adults increased lean body mass but not strength. Selling the muscle promise to a TikTok audience without that nuance is misleading by omission, even if no one said it directly.

What should you actually know?

CJC-1295 no DAC and ipamorelin are not FDA-approved drugs. They are research chemicals or, in some cases, compounded preparations. The FDA has taken action against compounding pharmacies producing these peptides, and their regulatory status is genuinely unsettled. Buying them from a brand called "Auralis Peptides" with no visible prescription requirement or medical oversight is a red flag, not a lifestyle choice.

The short-term safety profile of ipamorelin looks relatively clean in the studies that exist, but long-term data in healthy humans is essentially nonexistent. Nobody knows what repeated GH pulse amplification does to insulin sensitivity, cancer risk, or pituitary function over years of use. That's not a reason to panic, but it is a reason not to take TikTok captions as a clinical recommendation. If you're interested in peptide therapy, that conversation belongs with a licensed provider who can order baseline labs and actually monitor what's happening in your body.

The bottom line on this post

This video is effectively an advertisement wrapped in hashtags. The peptide combination it promotes has real pharmacological activity and some legitimate research behind it, but the implied benefits for muscle and sleep are being sold to a general audience without the caveats those claims require. The creator said nothing factually wrong, because they said almost nothing at all. But the post exists to move product, and that context matters when you're evaluating it.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Auralis Peptides | Biotech · TikTok creator

15.2K views on this video

CJC-1295 no DAC + IPAMORELIN de Auralis Peptides. #AuralisPeptides #hormonadelcrecimiento #musculos #cjc1295ipamorelin #descansoprofundo

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about cjc-1295 no dac has a half-life of roughly 30 minutes,?

CJC-1295 no DAC has a half-life of roughly 30 minutes, making it pharmacokinetically distinct from the DAC version studied by Teichman et al. (2006, JCEM). Most cited research uses the longer-acting DAC formulation.

What does the video say about ipamorelin's selectivity for gh release with minimal cortisol?

Ipamorelin's selectivity for GH release with minimal cortisol or prolactin impact was established by Raun et al. (1998, European Journal of Endocrinology) in animal models. Human data is limited.

What does the video say about the deep sleep angle has the most scientific support: ghrh?

The deep sleep angle has the most scientific support: GHRH analogs have been shown to increase slow-wave sleep in healthy men (Frieboes et al., 1995, Neuroendocrinology).

What does the video say about a 2007 meta-analysis in annals of internal medicine found gh?

A 2007 meta-analysis in Annals of Internal Medicine found GH supplementation in healthy adults increased lean mass but did not improve strength, complicating the muscle-building narrative.

What does the video say about neither cjc-1295 nor ipamorelin?

Neither CJC-1295 nor ipamorelin is FDA-approved. The FDA has taken enforcement action against compounding pharmacies producing these peptides, and their legal status for consumer sale is unsettled.

What does the video say about long-term safety data for repeated gh secretagogue use in healthy,?

Long-term safety data for repeated GH secretagogue use in healthy, non-deficient adults does not exist in the peer-reviewed literature. No one knows the multi-year risk profile.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Auralis Peptides | Biotech, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.